WEBULL
News
KNSA
46.68
-0.13%
-0.06
Weekly Report: what happened at KNSA last week (0302-0306)?
Weekly Report · 1d ago
A Look At Kiniksa Pharmaceuticals International’s Valuation After Strong 2025 Growth And ARCALYST Commercial Momentum
Simply Wall St · 3d ago
Kiniksa Pharmaceuticals CMO John F. Paolini Disposes of Common Shares
Reuters · 5d ago
How Investors Are Reacting To Kiniksa (KNSA) Turning ARCALYST Revenue Into Full-Year Profitability And Flexibility
Simply Wall St · 6d ago
Weekly Report: what happened at KNSA last week (0223-0227)?
Weekly Report · 03/02 09:38
Is Kiniksa Pharmaceuticals (KNSA) Still Attractive After A 114% One-Year Share Price Surge?
Simply Wall St · 02/27 05:29
Analysts’ Top Healthcare Picks: Acadia Healthcare (ACHC), Kiniksa Pharmaceuticals (KNSA)
TipRanks · 02/26 13:40
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), BioMarin Pharmaceutical (BMRN) and Kiniksa Pharmaceuticals (KNSA)
TipRanks · 02/26 09:50
Kiniksa Pharmaceuticals International (KNSA) Profitability Shift Tests Bullish High Growth Narratives
Simply Wall St · 02/26 03:42
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
Reuters · 02/25 21:02
The Analyst Verdict: Kiniksa Pharmaceuticals In The Eyes Of 4 Experts
Benzinga · 02/25 18:00
Kiniksa Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Dow Jones · 02/25 15:04
Kiniksa Pharmaceuticals Price Target Raised to $53.00/Share From $50.00 by Wells Fargo
Dow Jones · 02/25 15:04
Wells Fargo Maintains Overweight on Kiniksa Pharmaceuticals, Raises Price Target to $53
Benzinga · 02/25 14:54
Kiniksa Pharmaceuticals Is Maintained at Outperform by Wedbush
Dow Jones · 02/25 13:33
Kiniksa Pharmaceuticals Price Target Raised to $53.00/Share From $50.00 by Wedbush
Dow Jones · 02/25 13:33
Kiniksa price target raised to $53 from $50 at Wedbush
TipRanks · 02/25 13:29
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $53
Benzinga · 02/25 13:23
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Swing To Profit On Higher Quarterly Revenue
Simply Wall St · 02/25 00:43
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Protara Therapeutics (TARA) and Kiniksa Pharmaceuticals (KNSA)
TipRanks · 02/24 18:10
More
Webull provides a variety of real-time KNSA stock news. You can receive the latest news about Kiniksa Pharmaceuticals International, plc through multiple platforms. This information may help you make smarter investment decisions.
About KNSA
Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.